Director/PDMR Shareholding

Science in Sport PLC
10 July 2023
 

 

 

Science in Sport plc

 

("Company" or "Group")

 

 

Director/PDMR Shareholding

 

Science in Sport plc (AIM: SIS), the premium performance nutrition company serving elite athletes, sports enthusiasts and the gym lifestyle community, announces that it has been notified of the following transaction by a PDMR.

 

 

Notification of a Transaction pursuant to Article 19(1) of the EU Market Abuse Regulation (EU) No. 596/2014 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018.


1

Details of the person discharging managerial responsibilities/person closely associated


a.

Name

Lombard Odier Asset Management (Europe) Limited

 


2

Reason for notification

 


a.

Position/Status

PCA of Henry Turcan, Non-Executive Director

 


b.

Initial notification/

Amendment

Initial Notification


3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor


a.

Name

Science In Sport plc


b.

LEI

213800FWYWBJFJPPJ981


4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted


a.

Description of the financial instrument, type of instrument

Identification Code

Ordinary Shares of 10 pence each
 

GB00BBPV5329


b.

Nature of the transaction

Purchase of Ordinary Shares


 c.

Price(s) and volume(s)

Price(s)

Volume(s)

£0.12

900,000

 


d.

Aggregated information

- Aggregated Volume

- Price

 

N/A

 

e.

Date of the transaction

4 July 2023


f.

Place of the transaction

Outside a trading venue






















 

 

For further information, please contact:

 

Science in Sport plc

T: 020 7400 3700

Stephen Moon, CEO


Dan Lampard, CFO




Liberum (Nominated adviser and broker)

T: 020 3100 2000

Richard Lindley

Will Hall


 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings